Your medicine changed federal drug schedules in April. Almost nobody told you.

For fifty years, the federal government classed marijuana with heroin: Schedule I, "no currently accepted medical use." If you are a Colorado medical patient, that changed on April 28, 2026. And there is a decent chance nobody has told you. An order signed by the Acting Attorney General moved marijuana under state medical licenses from Schedule I to Schedule III, effective the day it published. Your state's cannabis science-and-policy forum has met three times since. On our transcripts of those meetings, the change has not come up once.

This page explains what actually moved, what it means at the dispensary counter, what the order conspicuously does not say, and the much bigger federal decision still being argued right now. Everything here traces to the primary documents.

What actually moved

Claim strength: Official source

The final rule (91 FR 22714, April 28, 2026) places two categories of marijuana in Schedule III:

1. FDA-approved drug products containing marijuana, and
2. marijuana "subject to a state-issued license to manufacture, distribute, and/or dispense marijuana or products containing marijuana for medical purposes."

That second category is Colorado's medical supply chain: the licensed grows, manufacturers, and dispensaries your medicine passes through.

The rule is equally explicit about what did not move: "any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a schedule I controlled substance." That includes all recreational-licensed product: a gummy chemically identical to the one at the medical counter, sold under a rec license, is still federally Schedule I.

What it means at the counter

Claim strength: Official source

Three concrete things, all from the rule's own text:

• The federal government now recognizes state medical dispensing. A state medical certification with the usual formalities is federally "sufficient to permit dispensing" at a registered dispensary, no federal prescription required. For fifty years the federal position was that your medicine had no medical use; the new rule writes your med card's paperwork into federal regulation.
• Colorado's medical businesses can now register with the DEA, through an expedited pathway where the state license is "conclusive evidence" of state-law authorization, registration must be granted absent specific public-interest problems, and DEA's registration portal is already live. State rules on labeling, security, and disposal are accepted as sufficient.
• The 280E tax penalty ends for medical licensees. The rule states that state licensees "will no longer be subject to" the federal deduction disallowance that has taxed cannabis businesses on gross rather than net income, while disclaiming any tax determination and pointing licensees to tax counsel. Whether past years get relief is only "encouraged" of the Treasury, not ordered.

Claim strength: Analysis

The tax point is not just a business story. 280E has been a large, invisible line item inside every price on a medical menu. Whether its removal reaches your receipt depends on competition, not on the rule.

What the order does not say, including about your jar

Claim strength: Open question

The rule's scope runs on the phrase "subject to a state medical marijuana license," and it defines that license as one to manufacture, distribute, or dispense. A patient does none of those things. The rule authorizes registered dispensaries to sell to state-authorized patients, and then goes silent. Nothing in the order states what schedule the product in your hand is after lawful purchase, and no provision touches the federal simple-possession statute. We looked for the answer in every document on this page's ledger; it is not there.

What protects patients in practice is what protected them before: the long-standing appropriations rider that bars federal funds from being used against state-compliant medical marijuana activity, which, per the Congressional Research Service, rescheduling neither strengthens nor weakens. The practical posture of a compliant Colorado patient did not get worse in April. But the cleanest question in cannabis law (what schedule is a patient's lawfully purchased medicine?) currently has no written federal answer, and we have found no one saying so out loud.

The bigger decision, still being argued

Claim strength: Official source

The April order covered medical. The question of moving marijuana to Schedule III generally (the proposal that made headlines in 2024) is a separate proceeding, restarted the same day by a notice of hearing after a December 2025 executive order directed the agency to finish the rulemaking "in the most expeditious manner." A formal evidentiary hearing (witnesses and cross-examination before a DEA administrative law judge) ran June 29 through July 15, 2026.

Claim strength: Analysis

What happens next, per the reporting from the hearing's close (the judge's scheduling order itself is not yet in our ledger): the parties' written closing arguments ("post-hearing briefs") are due August 17, 2026. The judge then writes a recommended decision on no set deadline; parties get twenty days to object; and the DEA Administrator makes the final call, also on no deadline. August 17 is not a decision day. It is the day the arguing ends and the deciding begins, with recreational-side product staying Schedule I throughout.

The Colorado silence

Claim strength: Analysis

Here is the part we cannot explain yet. Rescheduling was raised at Colorado's cannabis Science & Policy Forum in January 2026: a participant asked, if it "is going to be a reality here soon," how the state would harmonize, including on "how it deals with medical testing." Then it became a reality. On our transcripts, the forum has not discussed the consequences since: not the DEA registration window that opened for Colorado's own licensees, not what Schedule III means for the state reference lab's often-cited federal constraint (a constraint the lab described in January, accurately at the time, in Schedule I terms), and not the tax change rippling through the industry it regulates.

We are genuinely curious why, and we can think of an honorable answer: with the general rescheduling still undecided, an agency might reasonably wait for the ground to stop moving before rebuilding on it. But nobody has said that either. We'll be listening on September 4.

What we're watching

• August 17: post-hearing briefs close the record.
• The recommended decision, whenever it comes, and the Administrator's final rule after it.
• Whether Colorado's forum or agencies address the April order: registration uptake by Colorado licensees, testing-lab implications, any statement on harmonization.
• Treasury/IRS guidance on 280E, prospective and retrospective.
• Any written answer on patient possession: the open question above.